The pharmacokinetics of moxalactam were determined in eight patients with end stage renal disease who were undergoing chronic hemodialysis. The mean half-life of moxalactam in the interdialysis period was 19 h, with a range of 9 to 30 h. The mean half-life of moxalactam during dialysis was 4 ± 0.58 h. Serum levels of 30 ± 10 ,g/ml were present 24 h after a 1-g dose in the interdialysis period. A dose of 1 g at the end of each dialysis period in patients undergoing thrice-weekly hemodialysis would provide levels far in excess of the miniimal inhibitory levels against Enterobacteriaceae.
Moxalactam, a new fl-lactam, has remarkable in vitro activity against many clinically relevant gram-positive and gram-negative bacteria (11) . Clinical studies at our institution have shown moxalactam to be a useful agent in the treatment of serious infections due to multiply antibioticresistant bacteria (H. C. Neu and S. Subramaniam, manuscript in preparation). Since individuals with renal impairment frequently develop infections due to bacteria resistant to many antibiotics (2), we studied the pharmacokinetics of moxalactam administered intravenously to patients with severely depressed renal function in periods between dialysis and during chronic, intermittent hemodialysis. Blood flow was maintained at a constant rate of 250 to 300 ml/min. Dialysate flow rate was held constant at 600 ml/min. Arterial blood samples (5 ml) were obtained at 0, 15, 30, 60, 120, 180, 240, and 270 min. Five additional patients were given 1 g of moxalactam by a 5-min intravenous bolus in an interdialysis period. Venous blood samples were drawn at 1, 2, 3, 5, 6, and 24 h after injection.
MATERIALS AND METHODS
Blood was collected in evacuated glass tubes and allowed to clot at room temperature. The serum was separated by centrifugation, and all samples were stored frozen at -20°C until assayed simultaneously. The moxalactam content of the serum samples was determined by an agar well diffusion method with an Escherichia coli from our collection as the assay microorganism (11) . The assay could detect 0.3 gg/ml. Standard curves were prepared for each assay with pooled human serum which lacked antibacterial activity. Portions of dialysate obtained at the outflow drain were assayed by the same agar well technique. Flow rates were monitored with the machines, though we realized that this may have yielded an approximation of the flow. Standards for assay of dialysate were prepared in sterile potassium phosphate buffer (0.05 M; pH 7.0). All serum and dialysate samples were assayed in quadruplicate with agreement of ±5% from 0.3 to 80 ,ug/ml. Samples which gave results outside the linear part of the curve were diluted in normal human serum.
The semilogarithmic plot of the serum concentrations when plotted as time after intravenous injection conformed to a biexponential curve. Thus, two-compartment kinetics were used to define the intravenous study data (5, 8) . Regression lines were determined with a computer by the method of least squares. 
RESULTS
The serum curve for the patients on dialysis is shown in Fig. 1 . Mean serum level was 58.9 ± 5.7 ,tg/ml at 30 min, 47.1 ± 4.9 ,Ig/ml at 2 h, 40.6 ± 4.7 ,ug/ml at 3 h, and 27.7 ± 2.93 ,ug/ml at 4.5 h. The mean elimination half-life of moxalactam during hemodialysis was 40.6 h ( Table 1) .
The mean clearance of the drug was 47.8 ml/ min. The mean apparent volume of distribution was 15.8 liter/kg of body weight. Approximately 29% of the administered dose was recovered in the dialysate during the 4.5-h period of hemodialysis. In the interdialysis period, the mean half-life was 19 h, and the range was 9 to 30 h. The clearance of moxalactam was 7.85 ml/min, but the range of values was wide ( The drug yielded peak serum levels of 72 ,ug/ ml after a 5-min injection of 1 g. These levels are well in excess of those which would inhibit the majority of susceptible bacteria, although the exact serum and tissue concentrations of an antibiotic which are required to achieve cure of different types of infection are unknown. Young et al. (14) have presented data suggesting that those immunocompromised patients who, at peak, had serum levels of antibiotic which exceeded the minimal inhibitory concentration eightfold had a greater likelihood of clearing their infections. Utilizing this proposal, we could calculate the dose and frequency at which moxalactam should be administered to patients in renal failure whose creatinine clearances were -7 ml/min. Given the formula D = C Vd(le-$), where D is the maintenance dose, Vd is the volume of distribution at steady state, C is the target concentration, 8 is the rate constant for 0.5 I 2 3 4
S disappearance of drug from the bloodstream, HOURS and t is the dosing interval, we calculated that G. 1 This study demonstrates that the half-life of moxalactam is reduced during dialysis from 19 to 4 h. Since this manuscript was submitted, Lam et al. (9) reported a half-life of 4.4 ± 0.05 h during dialysis. There was some variation in reduction which could be attributed to differences in extrarenal elimination of the compound. However, a 4.5-h period of dialysis, which is a commonly used period, caused a 58% reduction in serum level. Nevertheless, the serum level after dialysis was far in excess of that needed to inhibit most Enterobacteriaceae with minimal inhibitory concentrations of 1 ,ug/ml which infect such patients. Indeed, only if one were dealing with P. aeruginosa or an anaerobic infection would another dose be required. Clearance of moxalactam may vary among studies of patients in renal failure, since protein binding of the drug, dialysis transmembrane pressure, dialyzer physical characteristics, and blood and dialysate flow rates differ in different institutions. Furthermore, splanchnic blood flow during dialysis differs markedly from that observed when such patients are off dialysis, and this will affect nonrenal clearance mechanisms.
In comparison with cephalosporin antibiotics (Table 2) , moxalactam accumulated as do cephalexin and cefazolin and to a greater degree than 
